Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study Posted byZacks Equity Research January 25, 2022 Leave a comment on Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.